Explore Our Resource Library

What are Targeted Protein Degraders? Traditional drug development depends upon the discovery of a small molecule that binds to the active site of a protein of interest (POI) and functionally blocks its activity. However, this type of ‘occupancy-driven’ pharmacology is only suitable for a narrow range of applications, as it requires the target to have both a well-defined binding pocket and established enzymatic activity. Consequently, an estimated 80-90% of the human proteome – including transcription factors, scaffolding proteins, and many other clinically relevant targets – is considered...

DNA-encoded libraries – DELs, for short – have attracted the attention of the pharmaceutical industry in recent years,...

The ability to target RNA with small-molecule drugs presents a powerful opportunity for therapeutic intervention. In...

Recent publications highlight an “evolving toolbox” of techniques and technologies implemented in covalent inhibitor...

What is affinity selection mass spectrometry (ASMS)? Affinity Selection Mass Spectrometry (ASMS) is a high throughput...